

Wherever you want to go in biotechnology, we can help you get there *faster...*

*If you are a scientist doing biotechnology research...or a business person looking to bring biotechnology research into commercial applications...you may want to consider becoming a Nature Biotechnology subscriber. Think of us as your "roadmap" to getting you where you want to go in biotechnology research, application, and commercialization.*



For more information or to order your personal subscription please contact us.

**In North and South America**  
Telephone 800-524-0384  
(outside the US) 615-377-3322  
Fax 615-377-0525  
e-mail: [subscriptions@natureny.com](mailto:subscriptions@natureny.com)

**In Australia**  
Telephone 61 (03) 9645 9444  
Fax 61 (03) 9645 7222

**In Japan**  
Telephone 81 (0) 3 3267 8751  
Fax 81 (0) 3 3267 8746  
e-mail: [subscriptions@naturejpn.com](mailto:subscriptions@naturejpn.com)

**In Europe and Rest of World**  
Telephone 44 (0) 171 843 4862  
Fax 44 (0) 171 843 4998  
e-mail: [subscriptions@nature.com](mailto:subscriptions@nature.com)

## RESOURCES

### PEOPLE

Maxim Pharmaceuticals (San Diego, CA) has announced three additions to its management team. **Geoffrey B. Altman** has been named senior director, marketing and sales. Previously, Mr. Altman was director of worldwide marketing at Agouron Pharmaceuticals. **F. David King**, formerly director of business development for DepoTech, has been named senior director, business development. And **Dean M. Work**, formerly director of licensing for Sandoz, has been named managing director of Maxim's vaccine division.

Gilead Sciences (Foster City, CA) has announced that **Paul Berg** has been appointed to its board of directors. Dr. Berg is Cahill Professor in Cancer Research in the department of biochemistry at the Stanford University School of Medicine. Dr. Berg also serves on the boards of Affymetrix and Transgene, and is the founder and a scientific advisor to DNAX Research Institute.

**Dan R. Burns** has been named president and CEO of ProScript (Cambridge, MA). Mr. Burns has been managing director of Bristol-Myers Squibb UK, and was most recently president and CEO of Trophix Pharmaceuticals.



Amgen (Thousand Oaks, CA) has announced that **Kathryn E. Falberg** has been named vice president of finance and CFO. She succeeds **Robert Attiyeh**, who will continue to serve as senior vice president, corporate development until June 30, and then will serve as a consultant to the company. Ms. Falberg previously served as vice president, corporate controller, and chief accounting officer.

Orchid Biocomputer (Princeton, NJ) has named **Samuel D. Isaly**, **Jeremy M. Levin**, and **Kenneth D. Noonan** to its board of directors, bringing its number to eight. Mr. Isaly is the principal of OrbiMed Advisors. Dr. Levin was most recently president, CEO, and chairman of Cadus. Dr. Noonan is a vice president at Booz-Allen & Hamilton.

**Ronald M. Lindsay** has been appointed vice president of preclinical research and development, and **Kevin Starr** has been named vice president of finance at Millennium BioTherapeutics (Cambridge, MA). Dr. Lindsay was previously vice president, neurobiology, at Regeneron Pharmaceuticals, where he was a founding scientist, and Mr. Starr was most recently corporate controller for Biogen.

**John H. Newman** has been promoted to senior vice president of Scios (Mountain View, CA). Since 1983, Mr. Newman has held various management and executive positions at Scios, most recently as vice president of legal affairs. He will continue to serve as general counsel and secretary.

GeneMedicine (The Woodlands, TX) has announced the appointment of **Bert W. O'Malley** to its board of directors. Dr. O'Malley is professor and chairman of the department of cell biology and director of the Baylor Center for Population Research and Reproductive Biology at Baylor College of Medicine.

**G. Kirk Raab** has been named chairman of the board and interim CEO of LXR Biotechnology (Richmond, CA). Mr. Raab has been a director since February 1998. **David Tomei**, a cofounder of the company, has been appointed executive vice president and chief scientific officer and will remain a director. Dr. Tomei served as chairman and CEO since November 1995, and has been a director since January 1996.

Bioniche (London, Ontario, Canada) has announced the appointment of **Vincent A. Salvatori** to the position of senior vice president of clinical operations. Dr. Salvatori most recently held the position of senior vice president of StressGen Biotechnologies.

Affymetrix (Santa Clara, CA) has appointed **Sue Siegel** to the newly created position of senior vice president, marketing and sales. Prior to joining Affymetrix, Ms. Siegel spent 9 years with Amersham Pharmacia Biotech, most recently serving as president of Hoefer Pharmacia Biotech's business unit.

NeoPharm (Bannockburn, IL) has appointed **Lewis Strauss** vice president of medical affairs. Dr. Strauss was an associate professor of pediatrics at Northwestern University School of Medicine's Lurie Cancer Center.

**John H. Waterman** has been appointed vice president, regulatory affairs at Aronex Pharmaceuticals (The Woodlands, TX). Mr. Waterman served most recently as vice president, regulatory affairs and quality assurance at Nycomed Amersham (formerly Amersham Holdings).

Cambridge NeuroScience (Cambridge, MA) has appointed **Harry Wilcox**, previously senior vice president of business development and CFO, as president and CEO. He was also named to the company's board of directors.